Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioMAP® Profiling Provides Insights into Toxicity of Nanomaterials, Failed Drugs and Environmental Chemicals

Published: Monday, March 19, 2012
Last Updated: Monday, March 19, 2012
Bookmark and Share
ToxCast high-throughput screening results using BioSeek’s BioMAP® human primary cell assay systems presented at society of toxicology.

Assessments of the biological activity of various nanomaterials and chemicals in the context of primary human cell biology were presented at the annual meeting of the Society of Toxicology by scientists from the U.S. Environmental Protection Agency and BioSeek, LLC.

The presented findings further demonstrate the value of BioMAP® human primary cell assay systems for both identifying critical bioactivities and potentially adverse effects of drugs, new materials and other compounds in a high-throughput format.

“Through our work with EPA, BioMAP is yielding a rich harvest of biological information on a wide variety of environmental and other chemicals and their potential effects on human health,” said Ellen Berg, Ph.D., General Manager of BioSeek.

Berg continued, “In addition to helping meet the goals of the ToxCast Program, which are aimed at developing high-throughput screening methods capable of predicting chemical toxicities, this information is continuing to enrich our BioMAP database. We view that resource as an increasingly valuable tool that can be mined to better understand the activities and potential safety of our pharmaceutical partners’ compounds in the context of human biology, prior to undertaking costly human clinical trials.”

In an oral presentation by EPA, various nanomaterials with varying cores and their ion and micro counterparts were tested for cytotoxicity in various cell types, for transcription factor activation in HepG2cells, and for protein bioactive profiling in eight BioMAP human primary cell systems at concentrations equivalent to human exposures of 24 hours to 45 years.

Analysis showed that nanomaterial cores are critical to bioactivities and their effects are often similar to those of related ions.

Comparing test results on nanomaterials to reference profiles of other compounds in the BioMAP database suggested further molecular targets and pathways affected by the tested nanomaterials that weren’t directly measured by the assays performed.

A poster presented by EPA and BioSeek collaborators discussed the biological profiling of the ToxCast Phase II Chemical Library in BioSeek’s primary human cell co-culture systems.

The Phase II library contains 1060 unique compounds including failed pharmaceuticals donated by industry partners, reference compounds known to be endocrine disrupters, carcinogens or reproductive/developmental toxicants, and other widely used chemicals, food and cosmetic additives, and proposed alternatives to current industrially used chemicals.

The chemicals were tested in a panel of BioMAP co-culture systems and classified based on their ability to cause overt cytotoxicity in various cells types and on their bioactivity profiles when compared to reference compounds.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Asterand’s Subsidiary BioSeek Extends Collaboration with Merck Serono
New three-year deal provides Merck Serono expanded access to BioSeek LLC’s BioMAP® platform.
Thursday, March 29, 2012
BioSeek and EPA Expand ToxCast™ Contract
BioMAP® Systems technology to profile the biological effects of compounds in a second phase of the agency’s ToxCast™ program.
Monday, July 06, 2009
BioSeek Licenses Two Novel Anti-Inflammatory Peptides
The two peptides, licensed from Amylin Pharmaceuticals, were identified as candidates for development in ongoing research collaboration between the two companies.
Friday, November 14, 2008
Scientific News
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!